Abstract

In the study, we report the comparative efficacy of the sodium hyaluronate gel vaginal application and promestriene cream which were tested to treat the gynecological symptoms of people who suffered from vaginal dryness. Method: 35 patients applied sodium hyaluronate vaginal gel one time a day for a period of two times a week during three weeks and other 33 patients using promestriene cream applied it every day for a period of three weeks also. Results: No significant difference was observed between vaginal application of sodium hyaluronate gel and promestriene cream, regarding both, as regarding the dryness of the intimate mucosa (p = 0.786), the attribute of moisturizing properties to the intimate mucosa (p = 0.142), the comfort sensation (p = 0.528), and no significant difference was observed regarding the fragrance of the product (p = 0.088). Conclusion: The similar results between vaginal application of both products support the use of sodium hyaluronate vaginal gel (Lubrinat®) in the initial approach of symptoms of vaginal dryness.

Highlights

  • Menopause is the permanent cessation of menses, after 12 consecutive months of amenorrhea

  • We report the comparative efficacy of the sodium hyaluronate gel vaginal application and promestriene cream which were tested to treat the gynecological symptoms of people who suffered from vaginal dryness

  • No significant difference was observed between vaginal application of sodium hyaluronate gel and promestriene cream, regarding both, as regarding the dryness of the intimate mucosa (p = 0.786), the attribute of moisturizing properties to the intimate mucosa (p = 0.142), the comfort sensation (p = 0.528), and no significant difference was observed regarding the fragrance of the product (p = 0.088)

Read more

Summary

Introduction

Menopause is the permanent cessation of menses, after 12 consecutive months of amenorrhea This can occur naturally or be induced secondary to the follicular depletion by bilateral oophorectomy, radiation to the ovaries, or by chemotherapy effects on ovarian follicular reserves [1] and the vaginal atrophy is common in postmenopausal women. On the vaginal dryness symptom, it is estimated that 10% to 50% of postmenopausal women have symptoms related, which include vulvovaginal irritation and dyspareunia [3] [4] These symptoms will progress markedly and will not be solved without treatment [5]. The epidemiologic data on post-menopause women evolution confirm that only 25.0% of them refer for treatment [6] [7] [8] These events have a significant impact on women’s quality of life [9] [10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call